Ondansetron Fresenius Kabi 2 mg/ ml Норвегия - норвежки - Statens legemiddelverk

ondansetron fresenius kabi 2 mg/ ml

fresenius kabi norge as - halden - ondansetronhydrokloriddihydrat - injeksjonsvæske, oppløsning - 2 mg/ ml

Palonosetron Fresenius Kabi 250 mikrog Норвегия - норвежки - Statens legemiddelverk

palonosetron fresenius kabi 250 mikrog

fresenius kabi norge as - palonosetronhydroklorid - injeksjonsvæske, oppløsning - 250 mikrog

Prevymis Европейски съюз - норвежки - EMA (European Medicines Agency)

prevymis

merck sharp & dohme b.v. - letermovir - cytomegalovirusinfeksjoner - antivirale midler til systemisk bruk - prevymis er indisert til profylakse cytomegalovirus (cmv) aktivering og sykdom i voksen cmv-avrusningsenhetene mottakere [r +] av en allogene haematopoietic stilk cellen transplantasjon (hsct). det bør vurderes å offisielle retningslinjer for riktig bruk av antivirale midler.

Reagila Европейски съюз - норвежки - EMA (European Medicines Agency)

reagila

gedeon richter - kariprazinhydroklorid - schizofreni - psykoleptiske - reagila er indisert for behandling av schizofreni hos voksne pasienter.

Carbidopa/Levodopa Fair-Med 12.5 mg / 50 mg Норвегия - норвежки - Statens legemiddelverk

carbidopa/levodopa fair-med 12.5 mg / 50 mg

fair-med healthcare gmbh - karbidopamonohydrat / levodopa - tablett - 12.5 mg / 50 mg

Carbidopa/Levodopa Fair-Med 25 mg / 100 mg Норвегия - норвежки - Statens legemiddelverk

carbidopa/levodopa fair-med 25 mg / 100 mg

fair-med healthcare gmbh - karbidopamonohydrat / levodopa - tablett - 25 mg / 100 mg

Ozalin 2 mg/ ml Норвегия - норвежки - Statens legemiddelverk

ozalin 2 mg/ ml

primex pharmaceuticals oy - midazolam - mikstur, oppløsning i endosebeholder - 2 mg/ ml

Byfavo Европейски съюз - норвежки - EMA (European Medicines Agency)

byfavo

paion deutschland gmbh - remimazolam besilate - bevisst sedasjon - psykoleptiske - remimazolam is indicated in adults for procedural sedation. remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.

Giotrif Европейски съюз - норвежки - EMA (European Medicines Agency)

giotrif

boehringer ingelheim international gmbh - afatinib - karsinom, ikke-småcellet lunge - antineoplastiske midler - giotrif som monoterapi er indisert for behandling ofepidermal vekstfaktor reseptor (egfr) tki-naive voksne pasienter med lokalt avansert eller metastatisk ikke-liten celle lunge kreft (nsclc) med aktivering av egfr mutasjon(s);lokalt avansert eller metastatisk nsclc av plateepitelkreft histology går på eller etter platinum-basert kjemoterapi.

Imatinib Actavis Европейски съюз - норвежки - EMA (European Medicines Agency)

imatinib actavis

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. effekten av imatinib på utfallet av bein marg transplantasjon har ikke fastsatt. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. erfaring med imatinib hos pasienter med mds/mpd forbundet med pdgfr gene re-ordninger er svært begrenset. det er ingen kontrollerte studier som viser en klinisk nytte eller økt overlevelse for disse sykdommer.